MCP
EW icon

Meridiem Capital Partners’s Edwards Lifesciences EW Stock Holding History

Meridiem Capital Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.7M Buy
858,921
+625,732
+268% +$52.4M 3.48% 3
2026
Q1 		$18.7M Buy
233,189
+118,424
+103% +$9.76M 1.22% 32
2025
Q4 		$9.78M Buy
+114,765
New +$9.42M 0.59% 54
2025
Q2 		– Sell
-372,822
Closed -$27M – 80
2025
Q1 		$27M Buy
372,822
+329,979
+770% +$23.6M 2.82% 12
2024
Q4 		$3.17M Buy
+42,843
New +$3M 0.28% 60

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Meridiem Capital Partners's EW Position: Q2 2026 in Review

Meridiem Capital Partners increased its Edwards Lifesciences (EW) stake by 268% in Q2 2026, buying an estimated $52.4M and bringing the position to 858,921 shares worth $77.7M. The position accounts for 3.48% of the portfolio, ranked #3.

Meridiem Capital Partners first reported a position in EW in Q4 2024 and has held it in 5 quarters since. 1,334 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Meridiem Capital Partners held 858,921 shares of Edwards Lifesciences worth $77.7M as of Q2 2026.
  • Meridiem Capital Partners bought 625,732 Edwards Lifesciences shares in Q2 2026, an estimated $52.4M.
  • Edwards Lifesciences made up 3.48% of Meridiem Capital Partners's portfolio in Q2 2026, its #3 holding.
  • Meridiem Capital Partners first reported a position in Edwards Lifesciences in Q4 2024 and has held it in 5 quarters since.
  • 1,334 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Meridiem Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.